Shire wins trial over ulcerative colitis drug

Shares in Shire have leapt after it announced Thursday evening that it had won a patent trial against Watson Laboratories over Lialda, one of its treatments for ulcerative colitis.

Shares in Shire have leapt after it announced Thursday evening that it had won a patent trial against Watson Laboratories over Lialda, one of its treatments for ulcerative colitis.

The group's subsidiary, Shire Developments, brought the litigation against the Florida-based firm which led to a five-day trial, the result of which was the judge confirming that Shire is entitled to an injunction, which he will issue separately.

The injunction prohibits the Food and Drug Association from approving the abbreviated new drug application (ANDA) formulation until the expiration of Shire's '720 patent in 2020.

In 2012 Lialda contributed $400m to Shire's sales, equal to 8.6% of its revenue, data from Bloomberg has shown.

"Shire is very pleased that the court has ruled in our favor. We rely on our patents to be able to continue to invest in therapies that bring value to our patients and their caregivers. This ruling supports the innovative therapies that we develop in order to improve the lives of ulcerative colitis patients," Roger Adsett, the head of Shire's GI Business Unit, said.

The share price leapt 5.33% to 2,037p by 09:00 Friday.

NR

Recommended

Three sustainable stocks that are doing well by doing good
Share tips

Three sustainable stocks that are doing well by doing good

Professional investor Peter Michaelis of the Liontrust Sustainable Investment Team picks three stocks to buy that are helping to create a cleaner, saf…
26 Jul 2021
Share tips of the week – 23 July
Share tips

Share tips of the week – 23 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
23 Jul 2021
Will Zoom’s $15bn purchase help it expand?
Tech stocks

Will Zoom’s $15bn purchase help it expand?

The videoconferencing platform became a household name during the pandemic, but it now needs new sources of growth. Alex Rankine reports
23 Jul 2021
Philip Morris goes “beyond nicotine”
Stocks and shares

Philip Morris goes “beyond nicotine”

US tobacco giant Philip Morris International has agreed to pay £1bn for British inhaler specialist Vectura.
23 Jul 2021

Most Popular

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
Three companies that are reaping the rewards of investment
Share tips

Three companies that are reaping the rewards of investment

Professional investor Edward Wielechowski of the Odyssean Investment Trust highlights three stocks that have have invested well – and are able to deal…
19 Jul 2021